Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
What insulin pump features and settings do you utilize in patients with diabetes and end stage renal disease on intermittent hemodialysis or home peritoneal dialysis?
Related Questions
Is the combination of SGLT2i and GLP 1 R agonist therapy contraindicated in patients who develop an episode of euglycemic DKA?
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Does injectable semaglutide have a higher glucose-lowering efficiency than oral semaglutide?
How do you approach insulin adjustments for a patient with type 1 diabetes who is not on an insulin pump and who has higher blood glucose levels in the late luteal phase of the menstrual cycle, when glucose levels are expected to rise?
How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
Would you recommend the 1-hour OGTT over the 2-hour OGTT for postpartum glucose tolerance testing in women with previous gestational diabetes?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
